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Abstract 
NZ2114 is a promising candidate for therapeutic application owing to its potent activity to Staphylococcus aureus. 
Our objective was to identify NZ2114 derivatives with improved activity through substitution of His16 and His18 
with residues Arginine and Lysine. Eight mutants were designed and expressed in Pichia pastoris X-33 via pPICZαA. 
Five of them exhibited strong antimicrobial activity against S. aureus at low minimal inhibitory concentrations (MICs) 
of 0.057–0.454 μM. Among them, H1, H2, and H3 showed ideal pharmacodynamic effects on methicillin-resistant 
S. aureus ATCC43300.  The total protein level of H1, H2, and H3 reached 1.70, 1.77 and 1.54 g/l at 120 h of induc-
tion in the 5-l fermenter, respectively. They killed over 99.9% of pathogens within 1.5 h at 2× and 4× MIC. The post 
antibiotic effect of H1, H2 and H3 to S. aureus ATCC43300 was 2.94, 1.75 and 1.55 h at 2× MIC, which was similar with 
their original peptide NZ2114 (1.43 h) and vancomycin (1.72 h). The fractional inhibitory concentration index (FICI) 
indicated indifferent effects between H1, H2, H3 and vancomycin, ampicillin, rifampicin. Additionally, they had low 
hemolysis and high stability in different environments (temperature, pH, proteases, and saline ions). All results indicate 
that H1, H2, and H3 can be produced in large-scale and have potential as therapeutic drugs against MRSA.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is 
one of the most common antimicrobial-resistant patho-
gens causing invasive infections (Dantes et  al. 2013), 
which can produce a series of toxins and shows frequent 
and sometimes multi-drug resistance to antimicrobials 
(Stefani et  al. 2012). According to the previous report, 
25–35% of healthy human individuals  carried S. aureus 
on the skin or mucous membranes (Wertheim et  al. 
2005). This means that up to two billion individuals may 
currently  carried S. aureus worldwide, and conservative 
estimates based on Dutch and US prevalence data  pre-
dicted that 2–53 million people  carried MRSA (Grund-
mann et al. 2010). MRSA infections can affect more than 
150,000 patients annually in the European Union (EU), 
resulting in extra in-hospital costs of EUR 380 million 
for EU healthcare systems (Köck et al. 2010). In another 
report, it is estimated that MRSA caused 171,200 health-
care-associated infections (HAIs) in Europe each year, 
which equals to 44% of all HAIs. MRSA also caused 5400 
extra deaths and over a million extra days of hospitalisa-
tion associated with the infection (Gould et al. 2012).
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The guidelines issued by Infectious Disease Society of 
America in 2011 recommend vancomycin, daptomycin, lin-
ezolid or clindamycin for MRSA infection (Liu et al. 2011). 
Although MRSA can be effectively treated by some antibi-
otics, sometimes their MIC values increased. Data from the 
tigecycline evaluation and surveillance trial showed that 
proportion of MRSA with MICs (vancomycin)  ≥2  mg/l 
increased from 5.6% in 2004 to 11.1% in 2009 (P < 0.001) 
(Hawser et al. 2011).
Antimicrobial peptides (AMPs) are potent drugs known 
for their broad-spectrum of  antimicrobial properties and 
particularly against antibiotic-resistant bacteria (Brogden 
and Brogden 2011). However, some flaws hamper the clini-
cal usage of AMPs, such as toxicity to normal mammalian 
cells and the lack of a cost-effective way of commercial-scale 
production (Cao et  al. 2015). Plectasin is a fungal defen-
sin from Pseudoplectania nigrella and is especially active 
against Gram-positive bacteria such as S. aureus (MIC50: 
16 μg/ml for methicillin-sensitive strains and 32 μg/ml for 
resistant strains) and Streptococcus pneumoniae (MIC50: 
1 μg/ml for both penicillin-sensitive and resistant strains) 
by binding with the pyrophosphate moiety of lipid II, the 
essential precursor of the cell wall (Mygind et  al. 2005; 
Ostergaard et  al. 2009; Schneider et  al. 2010). Peptide 
NZ2114 is a novel variant of plectasin (D9N, M13L, Q14R) 
that is significantly more potent than parental peptide 
(MIC50: 2 μg/ml for S. aureus and 0.25 μg/ml for S. pneu-
moniae) (Ostergaard et al. 2009; Zhang et al. 2014; Andes 
et al. 2009; Xiong et al. 2011). It also had long postantibiotic 
effect (PAE) (Zhang et al. 2014) and synergistic in combi-
nation with the conventionl antibiotics such as teicoplanin, 
moenomycin, and dalbavancin (Breidenstein et al. 2015). It 
had potent activities against S. aureus in rabbit meningitis, 
murine peritonitis, and thigh infection models (Ostergaard 
et al. 2009; Andes et al. 2009; Xiong et al. 2011). Addition-
ally, NZ2114 showed low or no cell toxicities, long-lasting 
serum stability and in vivo half-life (Brinch et al. 2010).
However, two histidine (His) residues exist in the 
sequence of NZ2114, which have a pKa of approximately 
6.0 and are largely unprotonated and uncharged at physi-
ological conditions (Kashiwada et al. 2016). It was found 
that some AMPs rich in His exhibited higher activity at 
low pH, when the histidine was positively charged, as 
compared with neutral pH. For example, LAH4 weakly 
disrupted the membrane at physiological conditions. The 
cell lysis activities of peptides LL-1a and LL-1c decreased 
up to four times as the solution pHs at 7.4 (Mason et al. 
2006). The arginine residues were previously suggested 
to be important for the antimicrobial activity of AMPs 
(Tu et al. 2009) and also to potentiate the internalization 
of peptides (Hansen et al. 2008). Arginine residues hav-
ing a more dispersed positive charge on their side chain 
guanidinium group, have been reported to enhance the 
electrostatic interactions between peptides and anionic 
lipids (Strandberg et al. 2002). Veiga et al. (2012) demon-
strated that the self-assembling β-hairpin peptides, hav-
ing a high content of arginine, were extremely effective 
to killing both gram-positive and gram-negative bacteria, 
including multi-drug resistant strains. Silva et al. (2014) 
found that arginine residues were crucial for the display 
of antimycobacterial activity. On the other side, the posi-
tive charge of lysine residues were considered to be criti-
cal for interacting with the anionic interface as a result 
of initial electrostatic interaction (Koba et  al. 2009). It 
showed that four positively charged lysine residues con-
centrated on the hydrophilic face of HPA3NT3-analog 
peptides, improved the amphipathic structure, and 
resulted in decrease of hemolysis (Gopal et al. 2009). The 
large loss of antimicrobial activity was also found when 
the C-terminal arginine and lysine residues of CL(14–
25) was replaced with alanine  residues (Taniguchi et  al. 
2014).
Therefore, to enhance the antimicrobial activity of 
NZ2114, replacement of the histidine at the 16th and 18th 
positions by arginine and lysine was performed. Eight 
mutants were designed and the antibacterial activities 
were evaluated. The peptides with excellent antibacterial 
property were chosen to test their pharmacodynamics, 
post antibiotic effect, synergy, hemolytic activity, and sta-
bility against S. aureus ATCC43300 (MRSA).
Materials and methods
Strains, plasmid and reagents
Escherichia coli DH5α, P. pastoris X-33 and pPICZαA 
vector were purchased from Invitrogen (Beijing, China). 
The test strains for the antimicrobial activity assays and 
their sources are listed in Additional file 1: Table S1. Van-
comycin, ampicillin, rifampicin and ciprofloxacin were 
purchased from the China Institute of Veterinary Drug 
Control. NZ2114 was prepared in our laboratory (Zhang 
et al. 2014). Restriction enzymes and T4 DNA ligase were 
purchased from New England Biolabs (NEB, Beijing, 
China). The kits for plasmid extraction and DNA puri-
fication were purchased from Tiangen (Beijing, China). 
Other chemical reagents were analytical grade.
Peptide design
The main structure of NZ2114 was kept unchangable to 
maintain the antimicrobial activity. Additionally, the histi-
dine residues in position 16 and 18 were mutated into argi-
nine or lysine. As results, eight derived peptides which H16 
and H18 were replaced by arginine or lysine were generated. 
The amino acid sequences and properties of the parental 
peptide and designed peptides were calculated by bioin-
formatics programs, including antimicrobial peptide calcu-
lator and predictor (http://aps.unmc.edu/AP/prediction/
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prediction_main.php) and ProtParam (ExPASy Proteomics 
Server: http://www.expasy.org/tools/protparam.html). All of 
the parameters are summarized in Table 1.
Construction of recombinant plasmid pPICH1–pPICH8
The codon-optimized gene sequences of H1–H8 (Addi-
tional file  1: Table S2) were designed by the Reverse 
Translate Tool (www.bioinformatics.org/sms2/rev_trans.
html), according to the preferential codon usage of P. pas-
toris (www.kazusa.or.jp/codon/). To ensure the integrity 
of the sequences in the expression process, the expres-
sion cassette included an XhoI recognition site, a P. pas-
toris Kex2 protease cleavage site, the H1–H8 genes, two 
stop codons, and an XbaI recognition site. The DNA 
sequences and pPICZαA vector were digested by XhoI 
and XbaI, gel-purified, and ligated together by T4 DNA 
ligase. The recombinant plasmids pPICH1–pPICH8 were 
transformed into E. coli DH5α, and positive cells were 
selected. The H1–H8 gene sequences were confirmed by 
DNA sequencing using the following two primers.
Primer 5′AOX1: 5′-GACTGGTTCCAATTGACAAG 
C-3′




Transformation and selection of positive transformants
The pPICH1–pPICH8 were linearized with PmeI and 
then transformed into the competent P. pastoris X-33 cells 
by electroporation following the Invitrogen’s instructions. 
The pPICZαA vector was also linearized and transformed 
into P. pastoris X-33 cells as a negative control. All zeocin-
resistant colonies were selected in YPDS plates (10  g/l 
yeast extract, 20  g/l peptone, 20  g/l glucose, 182.2  g/l 
sorbitol, 20 g/l agar, and 100 μg/ml zeocin).
Expression of H1–H8 in P. pastoris in 48‑well plates
A single colony of positive P. pastoris transformants 
was cultured at 29 °C (250 rpm) in 48-well plates con-
taining 500  µl BMGY medium (10  g/l yeast extract, 
20  g/l peptone, 10  ml/l glycerol, 13.4  g/l yeast nitro-
gen base, 400 µg/l biotin, and 100 ml/l 1 M potassium 
phosphate, pH 6.0). After 24 h, methanol (100%) was 
added each well to a final concentration of 0.5% (v/v), 
and the temperature was adjusted to 28  °C. Then 
methanol was repeatedly added every 24 h during the 
96  h induction time. The supernatant was collected 
by centrifugation at 10,000×g for 10  min and stored 
at −20 °C. The expression conditions of H1–H8 were 
determined by the inhibition zone assay against S. 
aureus ATCC25923 and Tricine-sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (Tricine-SDS-
PAGE) (Zhang et  al. 2014; Schägger 2006). Then the 
positive transformants with high inhibitory effect 
were selected to express in shake flasks (1-l shake 
flask containing 200-ml BMGY medium) using the 
same method.
Purification and identification of H1, H2, H3, H6, H8
The supernatant of 1-l shake flasks of H1, H2, H3, H6, 
and H8 was applied onto an SP Sepharose FF cation-
exchange column (GE Healthcare, UK) pre-equilibrated 
with binding buffer (20  mM sodium phosphate buffer, 
pH 6.7). H1, H2, H3, H6, and H8 were eluted from the 
column with elution buffer (20  mM sodium phosphate 
buffer, 600  mM NaCl, pH 6.7) at a rate of 6  ml/min, 
and the eluent of corresponding elution peaks were col-
lected. The eluent were analyzed by Tricine-SDS-PAGE 
and confirmed by MALDI-TOF MS at the Laboratory of 
Proteomics, Institute of Biophysics, Chinese Academy of 
Sciences according to the previously reported method 
(Zhang et al. 2014).
Table 1 Amino acid sequences and physicochemical properties of H1–H8
Name Sequence Molecular 
weight (Da)




NZ2114 GFGCNGPWNEDDLRCHNHCKSIKGYKGGYCAKGGFVCKCY 4417.0 8.62 + 3 −0.672 25.49 1.52
NZ16K (H1) GFGCNGPWNEDDLRCKNHCKSIKGYKGGYCAKGGFVCKCY 4408.0 8.84 +4 −0.690 11.42 1.54
NZ16R (H2) GFGCNGPWNEDDLRCRNHCKSIKGYKGGYCAKGGFVCKCY 4436.0 8.86 +4 −0.705 14.51 1.77
NZ18K(H3) GFGCNGPWNEDDLRCHNKCKSIKGYKGGYCAKGGFVCKCY 4408.0 8.84 +4 −0.690 31.41 1.54
NZ18R (H4) GFGCNGPWNEDDLRCHNRCKSIKGYKGGYCAKGGFVCKCY 4436.0 8.86 +4 −0.705 25.49 1.77
NZ16K18K (H5) GFGCNGPWNEDDLRCKNKCKSIKGYKGGYCAKGGFVCKCY 4399.0 9.02 +5 −0.708 17.34 1.56
NZ16K18R(H6) GFGCNGPWNEDDLRCKNRCKSIKGYKGGYCAKGGFVCKCY 4427.1 9.04 +5 −0.722 11.42 1.79
NZ16R18K (H7) GFGCNGPWNEDDLRCRNKCKSIKGYKGGYCAKGGFVCKCY 4427.1 9.04 +5 −0.722 20.43 1.79
NZ16R18R (H8) GFGCNGPWNEDDLRCRNRCKSIKGYKGGYCAKGGFVCKCY 4455.1 9.06 +5 −0.738 4.51 2.03
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Antimicrobial activity assays of H1, H2, H3, H6, and H8 
in vitro
The peptide solutions were diluted twofold with the 
range of final concentrations were 0.015–32  µg/ml 
(0.003–7.273 µM) for purified H1, H2, H3, H6, and H8. 
The test strains were grown in MHB medium at 37 °C to 
an OD600 of 0.4 and diluted to 1 × 105 CFU/ml. The 10 µl 
peptide and 90  µl cell suspension were added into each 
well. All assays were performed in triplicate. The antimi-
crobial activity of NZ2114 and vancomycin were tested 
as positive controls. The plates were incubated at 37  °C 
for 18–24 h. MIC was defined as the lowest peptide con-
centration of ones at which there was no visible growth 
(Tian et al. 2009).
Expression of H1, H2, H3 in P. pastoris in high‑density 
cultivation in fermentors
According to the results of the antimicrobial activ-
ity assays, H1, H2, and H3 were chosen to be expressed 
in the 5-l fermentor. A single colony of H1, H2, H3 was 
incubated in shaking flasks with 10  ml YPD medium at 
30 °C (250 rpm). Overnight cultures were inoculated into 
200 ml YPD medium and cultivated at 30 °C (250 rpm) to 
an OD600 of 5.0 and then transferred into a 5-l fermen-
tor (BIOSTAT®B plus, Sartorius Stedim Biotech) con-
taining 2 l basal salts medium (50 g/l NH4H2PO4, 20 g/l 
K2SO4, 15 g/l MgSO4·7H2O, 6 g/l KH2PO4, 0.4 g/l CaSO4, 
1.5  g/l KOH, 45  g/l glucose, and 4.8‰ PMT1). The pH 
was controlled at 5.5 using H3PO4 and NH4OH, and the 
temperature was maintained at 29 °C. When the glucose 
was exhausted, methanol was supplied from 1 to 7 ml/l/h 
during the first 6 h. Then methanol was supplied to main-
tain a relative dissolved oxygen (DO) content between 20 
and 40% under the speed of 6–8 ml/l/h (Bai et al. 2010). 
The fermentation liquid was collected every 24 h to quan-
tify the cell wet weight and the total protein level which 
was assayed by a Bradford protein assay kit (Tiangen Bio-
tech, Beijing, China). The expression of H1, H2, and H3 
was determined by Tricine-SDS-PAGE. The supernatant 
was purified in the same way as the 1-l shake flasks.
Time‑kill curve assay
Bacterial culture (S. aureus ATCC43300) was diluted to 
1 ×  105 CFU/ml and H1, H2, and H3 were added. The 
final concentration of H1, H2, and H3 was 1×  , 2× and 
4×  MIC, respectively. The mixture was cultivated at 
250 rpm, 37 °C. The 100-µl samples were taken from each 
flask at 0, 2, 4, 6, 8, 12 and 24 h of incubation, and serial 
dilutions of samples were plated to count visible colonies. 
Vancomycin was tested in the same way as a positive 
control and the culture without antimicrobial agent as a 
negative control (Xiong et al. 2011). All experiments were 
performed in triplicate.
The postantibiotic effect of H1, H2, H3 against S. aureus
The 100  µl peptides were added into tubes containing 
900 µl bacterial cultures (1 × 108 CFU/ml) to make their 
final peptide concentration to 1× , and 2× MIC, respec-
tively, and the mixture was cultured at 37  °C for 2  h. 
Tubes with 2× MIC vancomycin, 2× MIC NZ2114, and 
without antimicrobial agent were used as controls. After 
2 h, the drug was removed by diluting 1:103 into the MHB 
and incubated at 37  °C, 250 rpm. The sample was taken 
to plate counting every 1  h until the bacterial cultures 
become turbid. The PAE was calculated by the following 
formula: PAE = T − C, where T is the time needed for 
the count of CFU in the test culture to increase 1 log10 
(10-fold) above the 0 h and C is the time needed for the 
count of CFU in the untreated control culture to increase 
1 log10 above the 0 h (Giguère et al. 2012).
Synergism assays of H1, H2, H3 with conventional 
antibiotics
The MIC values of four antibiotics (vancomycin, ampicil-
lin, rifampicin and ciprofloxacin) to S. aureus ATCC43300 
were tested as the MIC assay described above. The pep-
tide solutions and antibiotics were diluted twofold with 
the final concentrations ranging from 1/16 to 8×  MIC, 
and added into 96-well plates in a checkerboard fash-
ion (White et al. 1996). The results of combination were 
evaluated by calculating the fractional inhibitory con-
centration index (FICI) of each combination. FIC of 
H1, H2, H3=MIC of H1, H2, H3, respectively, in com-
bination with antibiotic/MIC of H1, H2, H3 alone; FIC 
of antibiotics=MIC of antibiotic in combination with 
peptide/MIC of antibiotic alone; FICI =  FIC of H1, H2, 
H3+  antibiotic, respectively. The result of interaction 
between two antimicrobial drugs was determined accord-
ing to: FICI ≤ 0.5 refers to synergy, 0.5 < FICI ≤ 1 refers to 
additivity, 1 < FICI ≤ 4 refers to indifference, and FICI > 4 
is defined as antagonism (Tsuji and Rybak 2006).
Hemolytic assay
The mice blood cells were washed three times in stroke-
physiological saline solution (0.9% NaCl) and centrifuged 
at 4  °C, 2000  rpm for 5 min. A 50-μl cell was diluted to 
8% (v/v), added into 96-well plates, and mixed with 50-μl 
peptide to the final concentrations ranging from 0.23 
to 23.09  μM (1–128  μg/ml). The plates were incubated 
at 37  °C for 1  h, and centrifuged at 4  °C, 5000  rpm for 
5 min. The absorbance of supernatants was measured at 
540 nm, and 0 and 100% hemolysis was measured by 0.9% 
NaCl and 0.1% Triton X-100, respectively. The hemolysis 
percentages were calculated by the following equation: 
[(Abs540 nm in H1, H2, H3 solution − Abs540 nm in 0.9% 
NaCl)/(Abs540 nm in 0.1% Triton X-100 − Abs540 nm in 
0.9% NaCl)] ×100% (Jiao et al. 2015).
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Circular dichroism (CD) of H1, H2, H3
CD spectroscopy analysis of H1, H2, H3 [5.68 µM (25 µg/
ml) in ddH2O, 20  mM SDS, 50% TFE solution was car-
ried out in a MOS-450 spectropolarimeter (Bio-Logic, 
Grenoble)]. The samples were loaded into a 1  mm cell 
path at room temperature and the spectra were recorded 
from 195 to 245 nm three times.
Effect of pH, temperature, NaCl concentration 
and proteinase on the activity of H1, H2, H3
The effect of pH, temperature, NaCl concentration and 
proteinase on the activity of peptides was evaluated. Pep-
tides were diluted twofold, then adjusted to a pH range 
from 2.0 to 10.0 and incubated at 37  °C for 4  h. The 
thermal stability of purified peptides was determined 
after 1-h incubation of peptides at 4, 20, 40, 60, 80 and 
100 °C in deionized water, respectively. Aliquots of pep-
tides were incubated in various proteinases solutions 
[pepsin (pH 2.0), trypsin (pH 8.0), proteinase K (pH 7.0)] 
at a ratio of 1:10, w/w (proteinase: peptide) at 37  °C for 
3 h. For the ion stability, peptides were incubated in 50, 
100, 200, 300, 400, 500  mM sodium chloride solutions, 
respectively. Other methods and conditions were pre-




The net charge of derived peptides with one site mutants 
(H1, H2, H3 and H4) increased from +3 to +4, and the 
two sites mutants was +5 (H5, H6, H7 and H8). Due to 
the higher hydrophily of arginine and lysine, the grand 
average of hydropathicity (GRAVY) slightly decreased 
for one site mutants (from −0.672 to −0.690 for H1 and 
H3, and  to −0.705 for H2 and H4, respectively), and it 
further decreased for two sites mutants (−0.708 for H5, 
−0.722 for H6 and H7, and −0.738 for H8, respectively). 
The related high hydrophilicity may contribute to the 
surface contact of pathogens and peptides. The Boman 
index indicates the binding activity of drugs to protein, 
the large value may induce high negative side effects. 
Generally, it was considered that the value was acceptable 
as 1–3 kcal/mol (Weistroffer 2007). The Boman index of 
derived peptides was all between 1.54 and 2.03 kcal/mol, 
indicating they may have little negative side effects as 
novel antimicrobial agents (Table 1).
Expression of H1–H8 in Pichia pastoris in 48‑well plates
Thirty-six positive transformants of each peptide 
were screened by inhibition zone against S. aureus 
ATCC25923. The transformants showed various antimi-
crobial activity except H4 (date not shown). According to 
the diameter of inhibition zone, one transformant of each 
peptide was selected to analyze the expression condition 
by Tricine-SDS–PAGE. As shown in Additional file  1: 
Figure S1, there were no visible bands in the lane of H4, 
H5, H7, while H1, H2, H3, H6, and H8 displayed obvi-
ously bands, so they were chosen to the following assays.
Purification and identification of H1, H2, H3, H6, and H8
The supernatants of H1, H2, H3, H6, and H8 in 1-l 
shake flasks were purified. H1, H2, H3, H6, and H8 were 
detected by Tricine-SDS-PAGE from the eluent contain-
ing 20 mM sodium phosphate buffer, 600 mM NaCl, pH 
6.7 (Fig. 1a). Target bands around 4 kDa were detected, 
and there were no other bands (Fig.  1a). MALDI-TOF 
MS analysis indicated that only a target peak of 4428.97, 
4428.41, 4401.63, 4421.98, and 4392.18 Da from purified 
peptides (Fig.  1b–f) were detected, which were consist-
ent with their theoretical value of 4428, 4428, 4402, 4421, 
and 4393 Da, respectively.
Antimicrobial activity assays of H1, H2, H3, H6, and H8 
in vitro
H1, H2, H3, H6, and H8 showed a potent antimicro-
bial activity against Gram-positive bacteria, including 
three S. aureus strains (MIC: 0.057–0.454  μM), three 
Streptococcus suis strains (MIC: 0.007–0.057  μM), 
and two S. pneumonia strains (MIC: 0.227–1.818  μM) 
(Table  2). Due to the higher charge and hydrophily of 
arginine and lysine compared to histidine, their activity 
(MIC: 0.057–0.454  μM) against S. aureus ATCC43300 
(MRSA) was improved two to sixteen times than NZ2114 
(0.909  μM) and two to twelve times than vancomycin 
(0.714  μM). In addition, the activity of H1, H2, and H3 
against Methicillin-susceptible Staphylococcus aureus 
(MSSA ATCC25923, and ATCC6538) was  improved 
twice than NZ2114. Meanwhile, the too high charge and 
hydrophily did not result in the improved activity of H6 
and H8 against both MRSA (ATCC43300) and MSSA 
(ATCC6538). All of them could not inhibit Gram-nega-
tive pathogens (Table 2). Due to the excellent activity of 
H1, H2, and H3 against S. aureus, they were selected for 
the further pharmacodynamics study.
Expression of H1, H2, H3 in P. pastoris in high‑density 
cultivation in fermenters
H1, H2, and H3 were cultured and induced in 5-l fer-
menters. Target peptides in the supernatant were 
detected after 24  h of induction by Tricine-SDS-PAGE, 
and the concentration increased with induction time 
(Fig.  2a, c, e). The cell wet weight of H1, H2, and H3 
increased during the induction time and it up to 542.68, 
408.97, and 488.98  g/l at 120  h of induction, respec-
tively, and their total protein level reached 1.70, 1.77, and 
1.54 g/l, respectively (Fig. 2b, d, f ).
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Time‑killing curve assay
In vitro time killing curves were performed to evaluate 
the pharmacodynamic properties and bactericidal ability. 
In the absence of antimicrobial agent, the bacterial counts 
(log10 CFU/ml) reached to 15.17 for S. aures ATCCs43300 
at 24 h (Fig. 3). The time killing curves of H1, H2, and H3 
had a significant dose-dependent. The bacterial counts 
decreased to 2 log10 CFU/ml (a 99.9% reduction) in 6, 
1.5 and 1  h with 1×  , 2×  , and 4×  MIC of H1, respec-
tively. However, after 8 and 12 h, 1× and 2× MIC of H1 
had a regrowth and reached to 12.80 and 3.40 log10 CFU/
ml at 24 h, respectively (Fig. 3a). Meanwhile, the bacterial 
counts decreased to 2 log10 CFU/ml in 1.5, 1, and 0.5  h 
with 1× , 2× , and 4× MIC of H2, respectively, and main-
tained to 24  h without regrowth of pathogens (Fig.  3b). 
The H3 showed a similar trend to H1, but the bacterial 
counts of 1× MIC of H3 regrowed after 8 h of incubation 
(Fig. 3c). The efficacy of 1× MIC of H1 and H3 was equiv-
alent to 2× MIC of vancomycin, and all other concentra-
tions of peptides were better than that with vancomycin.
Fig. 1 Purification and identification of H1, H2, H3, H6, and H8. a Tricine-SDS-PAGE analysis of H1, H2, H3, H6, and H8 in fermentation supernatants 
of 1-l shake flasks. Lane M a total of 6 μl of protein molecular weight marker. Lane 1–5, 10 μl of purified H1, H2, H3, H6, and H8, respectively. b–f 
MALDI-TOF MS analysis of the purified H1, H2, H3, H6, and H8 fermentation supernatants in 1-l shake flasks
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The postantibiotic effect (PAE) of H1, H2, H3 against S. 
aureus
The PAE of H1 to ATCC43300 was 2.94  h at 2×  MIC, 
which was much longer compared with the 1.43 h for orig-
inal peptide NZ2114 and 1.72 h for vancomycin at 2× MIC 
(Table 3). The PAE of H2 and H3 at 1× MIC were 0.63 and 
0.55  h, respectively. They had similar values of 1.75 and 
1.55 h with NZ2114 and vancomycin at 2× MIC (Table 3).
Synergism assays of H1, H2, H3 with conventional 
antibiotics
The synergism effect of H1, H2 and H3 with traditional 
antibiotics which have different action mechanisms 
(vancomycin and ampicillin on cell wall, rifampicin on 
RNA, ciprofloxacin on DNA) was evaluated (Table  4). 
The MIC values of H1, H2, H3, vancomycin, ampicillin, 
rifampicin, and ciprofloxacin against ATCC43300 were 
0.056, 0.113, 0.056, 0.714, 5.724, 0.019, and 1.510  μM, 
respectively. When they were used with combination 
together, almost MIC values were not changed and 
some MIC values changed to 1/4 or 1/2×  MIC. How-
ever, the MIC value of ampicillin increased to 2× MIC 
with H2 and H3. Meanwhile, MICs of H2 and rifampicin 
increased twice when combined used with ciprofloxa-
cin and H3. The effect of interaction between H1, H2, 
H3 and antibiotics all showed as indifference with FICI 
from 1.25 to 3 (Table 4). These results were very differ-
ent from previous results of original peptide NZ2114 
(FICI: 0.125 for vancomycin and ampicillin) (Zhang 
et al. 2014).
Hemolytic assay
Different concentrations of H1, H2, H3, and NZ2114 
[0.23–23.09  μM (1–128  μg/ml)] were tested to observe 
their lysis activity on mice red blood cells (RBCs) in 
hemolysis assays (Additional file 1: Figure S2). The hemo-
lytic activity of original peptide NZ2114 maintained 
1.00% at its concertration from 0.23 to 23.09 μM. Due to 
the higher charge and hydrophilicity, derived peptides 
had higher hemolysis compared with NZ2114 but the 
value was very low in the MICs. H2 and H3 had little or 
no hemolytic activity at the concentration from 0.23 to 
7.27 μM (1–32 μg/ml). H3 had a hemolysis with 6.15% at 
14.55 μM (64 μg/ml), while H2 only had 1.51% hemolytic 
activity at 23.09 μM (128 μg/ml). H1 had higher hemol-
ysis than H2 and H3, which reached 5.99% at 7.27  μM 
(32 μg/ml).
CD spectra of H1, H2, H3
As shown in Fig.  4 and Table  5, NZ2114 had the  high 
α-helix content of 74.1 and 71.7% in ddH2O and 50% TFE, 
and the content of β-inverse parallel was very low (2.9 and 
1.3%). There was lower α-helix (24.8%) and higher antipar-
allel (18.9%) content in 20 mM SDS. The secondary struc-
tures of H1, H2 and H3 were different with NZ2114. The 
proportion of α-helix was 55.6, 35.6, and 35.1% and the 
Table 2 MIC assays of H1, H2, H3, H6, H8, NZ2114, and vancomycin against G+ and G− pathogens
NZ NZ2114, Van vancomycin, NT no test
a The data are from previous results (Zhang et al. 2014)
b The data are from previous results (Jiao et al. 2015)
Strains MIC (μM)
H1 H2 H3 H6 H8 NZ Van
Gram-positive bacteria
 S. aureus ATCC25923 0.014 0.028 0.014 0.028 0.028 0.028a 0.172
 S. aureus ATCC43300 0.057 0.114 0.057 0.114 0.454 0.909a 0.714
 S. aureus ATCC6538 0.057 0.057 0.114 0.114 0.227 0.114a 1.428
 S. suis CVCC3309 0.014 0.028 0.014 0.028 0.028 0.028 0.172b
 S. suis CVCC3928 0.007 0.014 0.028 0.014 0.057 0.028 0.172b
 S. suis CVCC606 0.007 0.028 0.028 0.014 0.028 0.028 0.172b
 S. pneumoniae CVCC1.8722 0.227 0.227 0.454 0.454 1.818 0.454 NT
 S. pneumoniae CVCC2350 0.227 0.227 0.227 0.454 1.818 0.909 NT
Gram-negative bacteria
 S. enteritidis CMCC50336 >7.273 >7.273 >7.273 >7.273 >7.273 >7.273 NT
 S. typhimurium ATCC14028 >7.273 >7.273 >7.273 >7.273 >7.273 >7.273 NT
 S. choleraesuis CVCC503 >7.273 >7.273 >7.273 >7.273 >7.273 >7.273 NT
 S. pullorum CVCC1789 >7.273 >7.273 >7.273 >7.273 >7.273 >7.273 NT
 E. coli CVCC195 >7.273 >7.273 >7.273 >7.273 >7.273 >7.273 NT
 E. coli CICC21530 >7.273 >7.273 >7.273 >7.273 >7.273 >7.273 NT
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β-inverse parallel was 3.8, 7.7, and 9.8% for H1, H2, and H3 
in ddH2O, respectively. And similar trends were observed 
in 20 mM SDS (51.6, 26.8, 35.2% for α-helix; 5.3, 10.3, and 
10.5% for β-inverse parallel). However, there was much 
higher α-helix content (82.9, 52.6, and 63.8% for H1, H2, 
and H3) and lower β-antiparallel proportion (0.4, 3.0, and 
2.5% for H1, H2, and H3) in 50% TFE. 
Effect of pH, temperature, NaCl concentration 
and proteinase on the activity of H1, H2, H3
The MIC values of H1 decreased twice (0.057  μM to 
0.028 μM) in pH 10 than other pHs and it increased twice 
(0.057–0.114 μM) in pH 6 than others for H3. Addition-
ally, the MIC of H2 maintained 0.114 μM in all five gra-
dients (Additional file  1: Table S3). Three peptides all 
Fig. 2 High-density cultivation of H1, H2, H3 in the fermentor level. a, c, e Tricine-SDS-PAGE analysis of H1, H2, H3 fermentation supernatants at dif-
ferent induction times, respectively. Lane 1–5 a total of 5-μl fermentation supernatants taken at 24, 48, 72, 96, 120 h. Lane M 6 μl protein molecular 
weight marker. b, d, f Time curve of the cell wet weight and total secreted protein levels of H1, H2, H3 during induction (three duplicate observa-
tions were made; bars represent standard error of mean)
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showed a high thermal stability, the MIC values of H1 and 
H3 increased twice only at 100 °C (0.057–0.114 μM), and 
H2 increased twice in 80 and 100  °C (0.114–0.227  μM) 
(Additional file  1: Table S4). As shown in Additional 
file  1: Table S5, the MIC values of H1 (0.057  μM) were 
not affected in the presence of different NaCl concentra-
tions, but H2 and H3 increased twice at 200 mM (0.114–
0.227 μM) and 400 mM (0.057–0.114 μM), respectively. 
The three peptides showed their own stability to different 
proteinases (Additional file 1: Table S6). The MIC value 
of H1 increased twice in pepsin (0.057–0.114  μM), and 
H2 and H3 increased twice in trypsin (0.227–0.454 μM) 
and proteinase K (0.057–0.114 μM), respectively.
Discussion
Currently, 2764 AMPs are registered in the antimicrobial 
peptide database (APD) (http://aps.unmc.edu/AP/main.
php). However, only few AMPs entered into clinical trials. 
The use of AMPs was primarily hampered by their low 
oral or intravenous stability, high toxicity, serum binding 
activity, low activity in physiological condition and so on 
(Mohammad et al. 2015). Plectasin and its derived pep-
tide NZ2114 had potent activity to S. aureus, which are 
the idea candidates for traditional drugs (Zasloff 2016). 
However, two histidine residues exist in the sequence of 
NZ2114, which are uncharged in the physiological condi-
tion (Kashiwada et al. 2016). To further improve the anti-
microbial activity and properties of NZ2114, new derived 
peptides are needed.
Although AMPs vary widely in length, structure, and 
source, they have some important common traits, such 
as positive charges, presumed to be important for inter-
action with the negatively charged surface of pathogens, 
and amphipathicity, which enables better combine with 
the hydrophilic surface and interact with the hydropho-
bic part of the microbial membrane (Silva et  al. 2014). 
The arginine and lysine are the key residues for AMPs 
which are stable charged and hydrophilic in physiologi-
cal condition. Many studies showed that AMPs having 
appropriate proportion of arginine and lysine had an 
improved amphipathicity and higher activity (Veiga et al. 
Fig. 3 Time-kill curves of H1 (a), H2 (b) and H3 (c). CK: S. aureus 
ATCC43300 (MRSA) were incubated in the presence of medium 
alone; Van-2MIC: S. aureus were incubated in the presence of the 
vancomycin(Van) at 2× MIC; H1-MIC, H1-2MIC, H1-4MIC, H2-MIC, 
H2-2MIC, H2-4MIC, H3-MIC, H3-2MIC, H3-4MIC: S. aureus were incu-
bated in the presence of H1, H2, H3 at 1× , 2× , 4× MIC, respectively; 
Three duplicate observation were made; Bars represent the standard 
error of the mean
Table 3 The PAE test for H1, H2, H3 against S. aureus
V-2MIC vancomycin at 2 × MIC, N-2MIC NZ2114 at 2 × MIC, H1-MIC, H1-2MIC, H2-MIC, H2-2MIC, H3-MIC, H3-2MIC H1, H2, H3 at 1 × , 2 × MIC, respectively
a In vitro observation values are the mean ± SD, n = 3
Strain PAE (h)a
V‑2MIC N‑2MIC H1‑MIC H1‑2MIC H2‑MIC H2‑2MIC H3‑MIC H3‑2MIC
S. aureus ATCC43300 1.72 ± 0.11 1.43 ± 2.02 0.90 ± 0.04 2.94 ± 0.07 0.63 ± 0.13 1.75 ± 0.04 0.55 ± 0.13 1.55 ± 0.07
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2012; Silva et al. 2014; Gopal et al. 2009; Taniguchi et al. 
2014). As results, eight derived peptides (H1–H8) which 
H16 and H18 were  replaced by arginine or lysine were 
generated.
All derived peptides were tried to express via P. pastoris 
but H4, H5 and H7 were not expressed. The antimicro-
bial activity of H1, H2, H3, H6 and H8 were assayed and 
H1, H2, and H3 had higher activity compared with origi-
nal peptide NZ2114. However, the activity of mutants 
H6 and H8 which had more net positive charges did not 
significantly increase (Table 2), which indicated that the 
electrostatic interaction and cell-penetrating was not the 
all bactericidal mechanisms of mutants.
Unlike some AMPs with a wide antimicrobial spec-
trum, H1, H2, and H3 showed a narrow spectrum and 
they mainly killed the Gram-positive bacterium, such 
as S. aureus, and Streptococci, and showed a strong 
antimicrobial activity (0.007–0.454  μM; Table  2), which 
was very stronger than the activities of plectasin and 
NZ2114 (Hara et al. 2008; Zhang et al. 2014). Especially, 
H1, H2, and H3 showed higher antimicrobial activ-
ity against MRSA (S. aureus ATCC43300) with MIC 
of 0.057, 0.114, and 0.057  μM than NZ2114 (0.909  μM) 
and vancomycin (0.714  μM). Their characteristics of 
narrow-spectrum antibiotic and low MIC values are very 
attractive for developing them as candidate agent against 
MRSA infection.
The lack of economic feasibility to manufacture AMPs 
at large-scale is another roadblock in the clinical imple-
mentation of AMPs (Findlay et  al. 2010). Majority of 
directly expressed AMPs, such as LL-37 (Hong et  al. 
2007), CecropinAD (Jin et al. 2009), and N2 (Yang et al. 
2016), showed unsatisfactory yields. In our previous 
works, Agplectasin (Mao et  al. 2013), NZ2114 (Zhang 
et al. 2014), and MP1106 (Cao et al. 2015) were expressed 
in P. pastoris X-33 in high level. Similarly, H1, H2, and 
H3 were expressed in P. pastoris X-33 with high yields, 
their total protein level in 5-l fermentation reached 1.70, 
1.77, and 1.54  g/l, respectively (Fig.  2b, d, f ). However, 
because the fermentation was performed in summer, the 
temperature cannot be  controlled at 29  °C as previous 
operation. To maintain the dissolved oxygen content, we 
had to reduce the flow rate, which lead to the partial los-
ing of yield. If the induction temperature can maintain 
at 29 °C, at which this key temperature is very important 
for its high expression in yeast (Li et al. 2001, 2007). the 
production of H1, H2, H3 may be further improved like 
their original peptide NZ2114 (2390  mg/l in 29  °C and 
2310 mg/l in 25 °C) (Zhang et al. 2014).
The PAE is a very important pharmacodynamics 
parameter in choosing of antibiotic dosage regimens in 
clinical use (Pankuch and Appelbaum 2009a). Obviously 
observed, the PAEs of H1, H2, and H3 increased with the 
concentration from 1× MIC to 2× MIC (Table 3). They 
showed similar values to vancomycin (2×  MIC: 1.72  h) 
and NZ2114 (2× MIC: 1.43 h). H1 also had comparative 
value (2× MIC: 2.94 h) to some conventional antibiotics, 
for instance, daptomycin (2.0 h), tigecycline (3.2 h), and 
arbekacin (3.0–3.2 h), respectively (Pankuch and Appel-
baum 2009b; Pankuch et al. 2003; Watanabe et al. 1997). 
Their appropriate PAE is critical to lengthen the inter-
val of administration, reduce the daily dosages, and thus 
potentially reduce potential drug resistance.
To combat antibiotic resistance, combination antibiotic 
therapy is practiced in the clinical use due  to its advan-
tages such as wider coverage, higher activity, bactericidal 
synergy and the inhibition on toxin production (Lei-
bovici et  al. 2010; Müller et  al. 2013). Vancomycin, one 
of the most effective antibiotics against MRSA, is often 
combined used with rifampicin, gentamicin, dalfopristin, 
Table 4 Combination effects of H1, H2, H3 with traditional 
antibiotics against S. aureus
Van vancomycin, Amp ampicillin, Rif rifampicin, Cip ciprofloxacin, H1-Van, 
H2-Van, H3-Van H1, H2, H3 in combination with vancomycin, respectively, 
H1-Amp, H2-Amp, H3-Amp H1, H2, H3 in combination with ampicillin, 
respectively, H1-Rif, H2-Rif, H3-Rif H1, H2, H3 in combination with rifampicin, 
respectively, H1-Cip, H2-Cip, H3-Cip, H1, H2, H3 in combination with 
ciprofloxacin, respectively, MICa the MIC of drug alone, MICc the MIC of the most 
effective combination
Combination Variety S. aureus ATCC43300
MICa (μM) MICc (μM) FIC FICI
H1-Van H1 0.056 0.056 1 2
Van 0.714 0.714 1
H1-Amp H1 0.056 0.014 0.25 1.25
Amp 5.724 5.724 1
H1-Rif H1 0.056 0.056 1 2
Rif 0.019 0.019 1
H1-Cip H1 0.056 0.028 0.5 1.5
Cip 1.510 1.510 1
H2-Van H2 0.113 0.113 1 2
Van 0.714 0.714 1
H2-Amp H2 0.113 0.113 1 3
Amp 5.724 11.450 2
H2-Rif H2 0.113 0.056 0.5 1.5
Rif 0.019 0.019 1
H2-Cip H2 0.113 0.227 2 2.5
Cip 1.510 0.755 0.5
H3-Van H3 0.056 0.028 0.5 1.5
Van 0.714 0.714 1
H3-Amp H3 0.056 0.056 1 3
Amp 5.724 11.450 2
H3-Rif H3 0.056 0.056 1 3
Rif 0.019 0.038 2
H3-Cip H3 0.056 0.056 1 1.5
Cip 1.510 0.755 0.5
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and β-lactams to slow the development of resistance 
and enhance the antibacterial activity. The synergis-
tic effect of H1, H2, and H3 is very different from their 
parent peptide NZ2114 (Zhang et al. 2014). The FICI of 
NZ2114 combined with ampicillin, and vancomycin to S. 
aureus ATCC43300 was 0.125, showing additivity effect 
(Zhang et  al. 2014). However, the indifference effects 
(1.25  ≤  FICI  ≤  3) were observed for all combinations 
between H1, H2, H3 and four traditional antibiotics to S. 
aureus ATCC43300 (Table  4), which might result from 
the changed antimicrobial property and mechanism and 
its details should be studied in our next research.
The plectasin and NZ2114 showed no hemolysis in 
rabbit and human RBCs (Yang et  al. 2011; Zhang et  al. 
2014). In this work, H1, H2, and H3 showed low hemoly-
sis in mice RBCs. Although the values were higher than 
NZ2114 due to the high charge and hydrophilicity, they 
were still  very low in the range of MICs. In addition, 
NZ2114 showed  the highest activity in pH value of 8.0 
and above 80% of initial activity was retained over a range 
of temperatures from 20 to 80  °C but maintained 20% 
activity at 100 °C (Zhang et al. 2014). Owing to contribu-
tion from the three pairs of disulfide bond into the stabil-
ity of structure, H1, H2, and H3 all had high stability with 
minor differences. H1 was not sensitive to NaCl concen-
tration, but sensitive to alkaline and high temperature 
environments. H2 was sensitive to high temperature and 
NaCl concentration, but not sensitive to different pHs 
environment. H3 was sensitive to high temperature and 
high NaCl concentration. Generally, no toxicity to eryth-
rocytes and high stability of pH, temperature, proteases, 
and saline ions of H1, H2 and H3 meet the key require-
ments of new antimicrobial agents.
In summary, series of novel AMPs were designed and 
successfully expressed in P. pastoris. Among them, H1, 
H2, and H3 had high yields (1.70, 1.77 and 1.54 g/l) in 5-l 
fermentor level. H1, H2, and H3 also showed strong anti-
microbial activity against S. aureus. They killed MRSA 
Fig. 4 CD spectra of H1, H2, and H3 in different solutions. a ddH2O; b 
20 mM SDS; c 50% TFE
Table 5 Percentages of secondary structure of NZ2114, H1, H2 and H3 in different solutions
NZ2114 H1 H2 H3
H2O 20 mM
SDS










Helix 74.1 24.8 71.7 55.6 51.6 82.9 35.6 26.8 52.6 35.1 35.2 63.8
Antiparallel 2.9 18.9 1.3 3.8 5.3 0.4 7.7 10.3 3.0 9.8 10.5 2.5
Parallel 2.4 9.2 2.9 5.1 5.7 1.4 8.3 9.9 5.5 8.2 8.1 4.0
Beta-turn 13.5 19.0 11.3 14.7 15.8 4.7 16.3 16.5 13.8 17.3 17.7 13.3
Rndm Coil 7.1 28.1 12.8 20.8 21.6 6.6 31.2 36.5 25.1 29.6 28.5 16.4
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strain ATCC43300 in a short time with low concentra-
tions and had long post antibiotic effect. Meanwhile, H1, 
H2, and H3 exhibited indifference effects when they were 
combined with conventional antibiotics. Furthermore, 
they had low toxicity to mice erythrocytes and  high 
stability. All results indicate that H1, H2, and H3 have 
potential as candidates for the therapeutic agents with 
the better properties than their native peptide NZ2114.
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